Most obesity drugs do not improve quality of life or heart health, analysis indicates

Дата публикации: 08-07-2026 22:30:04

Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life, and few show cardiovascular benefits at one year, according to an analysis of the latest evidence published by The BMJ.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Study raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic	0	9.05	28-01-2026
2	Weight‑loss jabs may create a new kind of yo‑yo dieting	0	7	10-07-2026
3	Medicare prescriptions for Wegovy jumped after approval for heart disease	0	7	09-07-2026
4	Popular GLP-1 weight-loss drugs like Ozempic slash heart attack and stroke risk	0	9.67	21-05-2026
5	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	7	8	31-07-2025
6	After weight loss, exercise improves cardiovascular health more than weight-loss medication	2	6	08-07-2026
7	After weight loss, exercise beats weight-loss drugs for heart health	0	9.66	21-07-2026
8	GLP-1 drugs could become personalized for individuals, study says	0	14.17	31-07-2026
9	GLP-1 drugs could become personalized for individuals, study says	0	14.17	01-08-2026
10	Popular GLP-1 weight-loss drugs linked to lower risks of addiction and overdose	0	9.68	03-06-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: -2. Информативность: 7. Источник: medicalxpress.com.